In addition, IL‐12‐activated NCR+ ILC3s have been shown to promote tumour rejection, not through cytotoxicity or IFNγ production, but by inducing expression of adhesion molecules like VCAM‐1 and ICAM‐1 on tumour vasculature, enhancing immune cell infiltration [134]. This evidence concerns the gene VCAM1 and neoplasm.